mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an prospective, single-center, single-arm, Simon's two-stage design, phase IIa study
for advanced/metastatic colorectal cancer (CRC) who had failed or were intolerant to standard
treatment. This study aims to evaluate the safety and efficacy of mFOLFOX6 combined with
dalpiciclib (SHR6390) in the treatment of advanced/metastatic colorectal cancer.